Kura Oncology (KURA) Net Cash Flow (2010 - 2026)

Kura Oncology (KURA) has 17 years of Net Cash Flow data on file, last reported at -$110.0 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$110.0 million, up 36.48% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.2 million (down 224.82% YoY), and the FY2025 annual result was -$75.4 million, down 140.27% from the prior year.
• Net Cash Flow declined to -$110.0 million in Q1 2026 per KURA's latest filing, from $53.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $175.0 million in Q4 2024 and troughed at -$173.2 million in Q1 2025.
• A 5-year average of -$8.6 million and a median of $4.2 million in 2024 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow surged 24627.27% in 2022, then tumbled 4235.46% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$39.1 million in 2022, then surged by 121.92% to $8.6 million in 2023, then jumped by 1939.89% to $175.0 million in 2024, then slumped by 69.25% to $53.8 million in 2025, then slumped by 304.45% to -$110.0 million in 2026.
• Business Quant data shows KURA's Net Cash Flow at -$110.0 million in Q1 2026, $53.8 million in Q4 2025, and $13.3 million in Q3 2025.